- Home
- Publications
- Publication Search
- Publication Details
Title
miR-655 Is an EMT-Suppressive MicroRNA Targeting ZEB1 and TGFBR2
Authors
Keywords
-
Journal
PLoS One
Volume 8, Issue 5, Pages e62757
Publisher
Public Library of Science (PLoS)
Online
2013-05-15
DOI
10.1371/journal.pone.0062757
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- MicroRNA control of epithelial–mesenchymal transition and metastasis
- (2012) Jinsong Zhang et al. CANCER AND METASTASIS REVIEWS
- Tumor-suppressive microRNA silenced by tumor-specific DNA hypermethylation in cancer cells
- (2012) Ken-ichi Kozaki et al. CANCER SCIENCE
- Roles for MicroRNAs in Conferring Robustness to Biological Processes
- (2012) Margaret S. Ebert et al. CELL
- The Tumor Suppressive MicroRNA miR-218 Targets the mTOR Component Rictor and Inhibits AKT Phosphorylation in Oral Cancer
- (2011) A. Uesugi et al. CANCER RESEARCH
- miR-152 Is a Tumor Suppressor microRNA That Is Silenced by DNA Hypermethylation in Endometrial Cancer
- (2011) T. Tsuruta et al. CANCER RESEARCH
- The ZEB1/miR-200 feedback loop controls Notch signalling in cancer cells
- (2011) Simone Brabletz et al. EMBO JOURNAL
- MiR-17-92 cluster regulates cell proliferation and collagen synthesis by targeting TGFB pathway in mouse palatal mesenchymal cells
- (2011) Ling Li et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- An autocrine TGF-β/ZEB/miR-200 signaling network regulates establishment and maintenance of epithelial-mesenchymal transition
- (2011) Philip A. Gregory et al. MOLECULAR BIOLOGY OF THE CELL
- Stabilization of phenotypic plasticity through mesenchymal-specific DNA hypermethylation in cancer cells
- (2011) Y Kurasawa et al. ONCOGENE
- The Promise of MicroRNA Replacement Therapy
- (2010) A. G. Bader et al. CANCER RESEARCH
- Frequent silencing of protocadherin 17 , a candidate tumour suppressor for esophageal squamous cell carcinoma
- (2010) Shigeo Haruki et al. CARCINOGENESIS
- Epithelial-Mesenchymal Transition in Cancer: Parallels Between Normal Development and Tumor Progression
- (2010) Douglas S. Micalizzi et al. JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA
- MicroRNA, hsa-miR-200c, is an independent prognostic factor in pancreatic cancer and its upregulation inhibits pancreatic cancer invasion but increases cell proliferation
- (2010) Jun Yu et al. Molecular Cancer
- Intronic miR-211 Assumes the Tumor Suppressive Function of Its Host Gene in Melanoma
- (2010) Carmit Levy et al. MOLECULAR CELL
- EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
- (2010) A Singh et al. ONCOGENE
- Comprehensive modeling of microRNA targets predicts functional non-conserved and non-canonical sites
- (2010) Doron Betel et al. GENOME BIOLOGY
- Up-regulation of miR-200 and let-7 by Natural Agents Leads to the Reversal of Epithelial-to-Mesenchymal Transition in Gemcitabine-Resistant Pancreatic Cancer Cells
- (2009) Y. Li et al. CANCER RESEARCH
- Epithelial-mesenchymal transition in cancer development and its clinical significance
- (2009) Masaaki Iwatsuki et al. CANCER SCIENCE
- miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma
- (2009) Mayuko Furuta et al. CARCINOGENESIS
- Epithelial-Mesenchymal Transitions in Development and Disease
- (2009) Jean Paul Thiery et al. CELL
- Functional screening identifies a microRNA, miR-491 that induces apoptosis by targeting Bcl-XL in colorectal cancer cells
- (2009) Haruo Nakano et al. INTERNATIONAL JOURNAL OF CANCER
- The basics of epithelial-mesenchymal transition
- (2009) Raghu Kalluri et al. JOURNAL OF CLINICAL INVESTIGATION
- Localization- and mutation-dependent microRNA (miRNA) expression signatures in gastrointestinal stromal tumours (GISTs), with a cluster of co-expressed miRNAs located at 14q32.31
- (2009) Florian Haller et al. JOURNAL OF PATHOLOGY
- The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs
- (2009) Ulrich Wellner et al. NATURE CELL BIOLOGY
- Involvement of Members of the Cadherin Superfamily in Cancer
- (2009) G. Berx et al. Cold Spring Harbor Perspectives in Biology
- The Transcriptional Repressor ZEB1 Promotes Metastasis and Loss of Cell Polarity in Cancer
- (2008) S. Spaderna et al. CANCER RESEARCH
- A Double-Negative Feedback Loop between ZEB1-SIP1 and the microRNA-200 Family Regulates Epithelial-Mesenchymal Transition
- (2008) C. P. Bracken et al. CANCER RESEARCH
- Exploration of Tumor-Suppressive MicroRNAs Silenced by DNA Hypermethylation in Oral Cancer
- (2008) K.-i. Kozaki et al. CANCER RESEARCH
- Frequent silencing of a putative tumor suppressor gene melatonin receptor 1 A (MTNR1A) in oral squamous-cell carcinoma
- (2008) Erina Nakamura et al. CANCER SCIENCE
- Identification of SMURF1 as a possible target for 7q21.3-22.1 amplification detected in a pancreatic cancer cell line by in-house array-based comparative genomic hybridization
- (2008) Ayako Suzuki et al. CANCER SCIENCE
- Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers
- (2008) Michèle Sabbah et al. DRUG RESISTANCE UPDATES
- A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells
- (2008) Ulrike Burk et al. EMBO REPORTS
- The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2
- (2008) S.-M. Park et al. GENES & DEVELOPMENT
- The miR-200 Family Inhibits Epithelial-Mesenchymal Transition and Cancer Cell Migration by Direct Targeting of E-cadherin Transcriptional RepressorsZEB1andZEB2
- (2008) Manav Korpal et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1
- (2008) Philip A. Gregory et al. NATURE CELL BIOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now